idhifa
(enasidenib mesylate)Celgene Corporation
Usage: IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH2 mutation, confirmed by an FDA-approved test.
Celgene Corporation drugs
10 results
inrebic - fedratinib hydrochloride capsule
(Fedratinib Hydrochloride)Celgene Corporationistodax - romidepsin
(Romidepsin)Celgene Corporationonureg - azacitidine tablet, film coated
(Azacitidine)Celgene Corporationpomalyst
(pomalidomide)Celgene CorporationUsage: POMALYST is indicated for adult patients with multiple myeloma who have received at least two prior therapies and show disease progression, as well as for treating AIDS-related and non-AIDS-related Kaposi sarcoma in adults following failure of other therapies.reblozyl - luspatercept injection, powder, lyophilized, for solution
(Luspatercept)Celgene Corporationrevlimid
(Lenalidomide)Celgene CorporationUsage: REVLIMID is indicated for adult patients with multiple myeloma (MM), myelodysplastic syndromes (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). It is used in combination with dexamethasone, rituximab products, or as maintenance therapy post-transplant. Not recommended for chronic lymphocytic leukemia (CLL).thalomid - thalidomide capsule
(Thalidomide)Celgene Corporationvidaza - azacitidine injection, powder, lyophilized, for solution
(Azacitidine)Celgene Corporationzeposia - ozanimod hydrochloride capsule
(Ozanimod Hydrochloride)Celgene Corporation